Neuroadaptive changes and behavioral effects after a sensitization regime of MDPV

Fecha de publicación

2020-01-20T12:19:53Z

2020-01-20T12:19:53Z

2018-10-12

2020-01-20T12:19:53Z

Resumen

3,4-methylenedioxypyrovalerone (MDPV) is a synthetic cathinone with cocaine-like properties. In a previous work, we exposed adolescent mice to MDPV, finding sensitization to cocaine effects, and a higher vulnerability to cocaine abuse in adulthood. Here we sought to determine if such MDPV schedule induces additional behavioral-neuronal changes that could explain such results. After MDPV treatment (1.5 mg·kg-1, twice daily, 7 days), mice were behaviorally tested. Also, we investigated protein changes in various brain regions MDPV induced aggressiveness and anxiety, but also contributed to a faster habituation to the open field. This feature co-occurred with an induction of ΔFosB in the orbitofrontal cortex that was higher than its expression in the ventral striatum. Early after treatment, D2R:D1R ratio pointed to a preponderance of D1R but, upon withdrawal, the ratio recovered. Increased expression of Arc, CDK5 and TH, and decrease in DAT protein levels persisted longer after withdrawal, pointing to a neuroplastic lasting effect similar to that involved in cocaine addiction. The implication of the hyperdopaminergic condition in the MDPV-induced aggressiveness cannot be ruled out. We also found an initial oxidative effect of MDPV, without glial activation. Moreover, although initially the dopaminergic signal induced by MDPV resulted in increased ΔFosB, we did not observe any change in NFκB or GluA2 expression. Finally, the changes observed after MDPV treatment could not be explained according to the autoregulatory loop between ΔFosB and the epigenetic repressor G9a described for cocaine. This provides new knowledge about the neuroadaptive changes involved in the vulnerability to psychostimulant addiction.

Tipo de documento

Artículo


Versión aceptada

Lengua

Inglés

Publicado por

Elsevier Ltd

Documentos relacionados

Versió postprint del document publicat a: https://doi.org/10.1016/j.neuropharm.2018.10.005

Neuropharmacology, 2018, vol. 144, p. 271-281

https://doi.org/10.1016/j.neuropharm.2018.10.005

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

cc-by-nc-nd (c) Elsevier Ltd, 2018

http://creativecommons.org/licenses/by-nc-nd/3.0/es

Este ítem aparece en la(s) siguiente(s) colección(ones)